Aggrecanases and cartilage matrix degradation

The loss of extracellular matrix macromolecules from the cartilage results in serious impairment of joint function. Metalloproteinases called 'aggrecanases' that cleave the Glu373–Ala374 bond of the aggrecan core protein play a key role in the early stages of cartilage destruction in rheumatoid arthritis and in osteoarthritis. Three members of the ADAMTS family of proteinases, ADAMTS-1, ADAMTS-4 and ADAMTS-5, have been identified as aggrecanases. Matrix metalloproteinases, which are also found in arthritic joints, cleave aggrecans, but at a distinct site from the aggrecanases (i.e. Asn341–Phe342). The present review discuss the enzymatic properties of the three known aggrecanases, the regulation of their activities, and their role in cartilage matrix breakdown during the development of arthritis in relation to the action of matrix metalloproteinases.

[1]  A. Barrett [54] α2-Macroglobulin , 1981 .

[2]  H. Burkhardt,et al.  Oxygen radicals as effectors of cartilage destruction. Direct degradative effect on matrix components and indirect action via activation of latent collagenase from polymorphonuclear leukocytes. , 1986, Arthritis and rheumatism.

[3]  J. Pelletier,et al.  Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. , 1989, The Journal of clinical investigation.

[4]  J. Sandy,et al.  Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. , 1991, The Journal of biological chemistry.

[5]  T. Hardingham,et al.  Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. , 1991, The Journal of biological chemistry.

[6]  T. Hardingham,et al.  The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. , 1992, The Journal of biological chemistry.

[7]  L. Lohmander,et al.  The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. , 1992, The Journal of clinical investigation.

[8]  T. Wolfsberg,et al.  A potential fusion peptide and an integrin ligand domain in a protein active in sperm–egg fusion , 1992, Nature.

[9]  L. Hayman,et al.  Correspondence , 1992, Neuroradiology.

[10]  C. Maniglia,et al.  N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. , 1992, The Biochemical journal.

[11]  M. Lark,et al.  Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. , 1992, The Journal of biological chemistry.

[12]  H. C. Robinson,et al.  Mechanism of catabolism of aggrecan by articular cartilage. , 1992, Archives of biochemistry and biophysics.

[13]  L. Lohmander,et al.  The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. , 1993, Arthritis and rheumatism.

[14]  D. Howell,et al.  Joint cartilage degradation : basic and clinical aspects , 1993 .

[15]  P. Bork,et al.  The CUB domain. A widespread module in developmentally regulated proteins. , 1993, Journal of molecular biology.

[16]  M. Seldin,et al.  Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP‐3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10 , 1994, Developmental dynamics : an official publication of the American Association of Anatomists.

[17]  Y. Nabeshima,et al.  A metalloprotease-disintegrin participating in myoblast fusion , 1995, Nature.

[18]  J. V. Van Beeumen,et al.  Characterization and Partial Amino Acid Sequencing of a 107-kDa Procollagen I N-Proteinase Purified by Affinity Chromatography on Immobilized Type XIV Collagen (*) , 1995, The Journal of Biological Chemistry.

[19]  R. Maciewicz,et al.  Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. , 1996, The Journal of clinical investigation.

[20]  B. Castner,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. , 1997, Nature.

[21]  G. Rubin,et al.  Kuzbanian Controls Proteolytic Processing of Notch and Mediates Lateral Inhibition during Drosophila and Vertebrate Neurogenesis , 1997, Cell.

[22]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[23]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[24]  J. Weidner,et al.  Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis. , 1997, Osteoarthritis and cartilage.

[25]  J. Weidner,et al.  Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. , 1997, The Journal of clinical investigation.

[26]  W. Li,et al.  Up‐regulation of tissue inhibitor of metalloproteinases‐3 gene expression by TGF‐β in articular chondrocytes is mediated by serine/threonine and tyrosine kinases , 1998, Journal of cellular biochemistry.

[27]  P. Slocombe,et al.  TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. , 1998, FEBS letters.

[28]  P. Slocombe,et al.  TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3 , 1998 .

[29]  B. Lämmle,et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1998, The New England journal of medicine.

[30]  J. Mudgett,et al.  Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. , 1998, Arthritis and rheumatism.

[31]  T. W. Mak,et al.  - α 2 -Macroglobulin , 1998 .

[32]  J. Mort,et al.  Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. , 1998, The Biochemical journal.

[33]  M. Zafarullah,et al.  Oncostatin M up-regulates tissue inhibitor of metalloproteinases-3 gene expression in articular chondrocytes via de novo transcription, protein synthesis, and tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms. , 1998, Journal of immunology.

[34]  H. Tsai,et al.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. , 1998, The New England journal of medicine.

[35]  R. Schneiderman,et al.  Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. , 1998, Archives of biochemistry and biophysics.

[36]  K. Matsushima,et al.  ADAMTS-1 Is an Active Metalloproteinase Associated with the Extracellular Matrix* , 1999, The Journal of Biological Chemistry.

[37]  J. V. van Meurs,et al.  Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. , 1999, Arthritis and rheumatism.

[38]  C. Little,et al.  Expression of ADAMTS homologues in articular cartilage. , 1999, Biochemical and biophysical research communications.

[39]  J. V. van Meurs,et al.  Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. , 1999, Arthritis and rheumatism.

[40]  R. Magolda,et al.  Aggrecanase: A Target for the Design of Inhibitors of Cartilage Degradation , 1999, Annals of the New York Academy of Sciences.

[41]  R. Wynn,et al.  Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family* , 1999, The Journal of Biological Chemistry.

[42]  R. Wynn,et al.  Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. , 1999, Science.

[43]  P. Rakic,et al.  Processing of the notch ligand delta by the metalloprotease Kuzbanian. , 1999, Science.

[44]  J. Trzăskos,et al.  Generation and Characterization of Aggrecanase , 1999, The Journal of Biological Chemistry.

[45]  M. Iruela-Arispe,et al.  METH-1, a Human Ortholog of ADAMTS-1, and METH-2 Are Members of a New Family of Proteins with Angio-inhibitory Activity* , 1999, The Journal of Biological Chemistry.

[46]  J. Pelletier,et al.  Expression of the tissue inhibitor of metalloproteinases (TIMP) gene family in normal and osteoarthritic joints , 1999, Rheumatology International.

[47]  P. Roughley,et al.  Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. , 1999, The Biochemical journal.

[48]  J. Nardi,et al.  Expression of lacunin, a large multidomain extracellular matrix protein, accompanies morphogenesis of epithelial monolayers in Manduca sexta. , 1999, Insect biochemistry and molecular biology.

[49]  S. Hockfield,et al.  Brain-enriched Hyaluronan Binding (BEHAB)/Brevican Cleavage in a Glioma Cell Line Is Mediated by a Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS) Family Member* , 2000, The Journal of Biological Chemistry.

[50]  S. Munteanu,et al.  Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explant cultures. , 2000, Arthritis and rheumatism.

[51]  H. Yokota,et al.  ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motifs) is transcriptionally induced in beta-amyloid treated rat astrocytes , 2000, Neuroscience Letters.

[52]  K. Brew,et al.  TIMP-3 Binds to Sulfated Glycosaminoglycans of the Extracellular Matrix* , 2000, The Journal of Biological Chemistry.

[53]  J. Fox,et al.  ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. , 2000, Biochemical and biophysical research communications.

[54]  T. Burn,et al.  The Thrombospondin Motif of Aggrecanase-1 (ADAMTS-4) Is Critical for Aggrecan Substrate Recognition and Cleavage* , 2000, The Journal of Biological Chemistry.

[55]  R. Leduc,et al.  Characterization of METH-1/ADAMTS1 Processing Reveals Two Distinct Active Forms* , 2000, The Journal of Biological Chemistry.

[56]  C. Little,et al.  Mechanisms involved in cartilage proteoglycan catabolism. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[57]  K. Matsushima,et al.  ADAMTS‐1 cleaves a cartilage proteoglycan, aggrecan , 2000, FEBS letters.

[58]  J. Harwood,et al.  n-3 Fatty Acids Specifically Modulate Catabolic Factors Involved in Articular Cartilage Degradation* , 2000, The Journal of Biological Chemistry.

[59]  R. Maciewicz,et al.  Mutations in the Interglobular Domain of Aggrecan Alter Matrix Metalloproteinase and Aggrecanase Cleavage Patterns , 2000, The Journal of Biological Chemistry.

[60]  E. Bartnik,et al.  Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[61]  A. Baici,et al.  The relative importance of cysteine peptidases in osteoarthritis. , 2000, The Journal of rheumatology.

[62]  T. Hardingham,et al.  Generation and Novel Distribution of Matrix Metalloproteinase-derived Aggrecan Fragments in Porcine Cartilage Explants* , 2000, The Journal of Biological Chemistry.

[63]  T. Burn,et al.  Sites of Aggrecan Cleavage by Recombinant Human Aggrecanase-1 (ADAMTS-4)* , 2000, The Journal of Biological Chemistry.

[64]  P. Slocombe,et al.  The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3 , 2000, FEBS letters.

[65]  M. Tortorella,et al.  Age-related Changes in Aggrecan Glycosylation Affect Cleavage by Aggrecanase* , 2000, The Journal of Biological Chemistry.

[66]  P. Roughley,et al.  Catabolism of Proteoglycans , 2000 .

[67]  E. Ohuchi,et al.  Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. , 2000, Arthritis and rheumatism.

[68]  B. Tang,et al.  ADAMTS: a novel family of extracellular matrix proteases. , 2001, The international journal of biochemistry & cell biology.

[69]  D. Woolley,et al.  Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. , 2001, Arthritis and rheumatism.

[70]  M Kashiwagi,et al.  TIMP-3 Is a Potent Inhibitor of Aggrecanase 1 (ADAM-TS4) and Aggrecanase 2 (ADAM-TS5)* , 2001, The Journal of Biological Chemistry.

[71]  R. Mason,et al.  The STR/ort mouse and its use as a model of osteoarthritis. , 2001, Osteoarthritis and cartilage.

[72]  J. Sandy,et al.  Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. , 2001, The Biochemical journal.

[73]  J. Fischer,et al.  Versican V1 Proteolysis in Human Aorta in Vivo Occurs at the Glu441-Ala442 Bond, a Site That Is Cleaved by Recombinant ADAMTS-1 and ADAMTS-4* , 2001, The Journal of Biological Chemistry.

[74]  M. Sasaki,et al.  A disintegrin and metalloprotease with thrombospondin type1 motifs (ADAMTS-1) and IL-1 receptor type 1 mRNAs are simultaneously induced in nerve injured motor neurons. , 2001, Brain research. Molecular brain research.

[75]  H. Nagase Aggrecanases in cartilage matrix breakdown , 2001 .

[76]  G. de Nanteuil,et al.  Effects of ceramide on aggrecanase activity in rabbit articular cartilage. , 2001, Biochemical and biophysical research communications.

[77]  D. Eyre,et al.  Procollagen II Amino Propeptide Processing by ADAMTS-3 , 2001, The Journal of Biological Chemistry.

[78]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[79]  C. P. Leblond,et al.  Enzymes active in the areas undergoing cartilage resorption during the development of the secondary ossification center in the tibiae of rats ages 0–21 days: I. Two groups of proteinases cleave the core protein of aggrecan , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[80]  R. Maki,et al.  Expression and activity of ADAMTS-5 in synovium. , 2001, European journal of biochemistry.

[81]  J. Mort,et al.  Articular cartilage and changes in arthritis: Matrix degradation , 2001, Arthritis research.

[82]  Douglas K. Anderson,et al.  Intact Aggrecan and Fragments Generated by Both Aggrecanse and Metalloproteinase-Like Activities Are Present in the Developing and Adult Rat Spinal Cord and Their Relative Abundance Is Altered by Injury , 2001, The Journal of Neuroscience.

[83]  K. Tanzawa,et al.  Inhibition of ADAMTS4 (aggrecanase‐1) by tissue inhibitors of metalloproteinases (TIMP‐1, 2, 3 and 4) , 2001, FEBS letters.

[84]  R. Mason,et al.  Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice. , 2001, Arthritis and rheumatism.

[85]  R. Magolda,et al.  Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. , 2001, Journal of medicinal chemistry.

[86]  K. Hillan,et al.  Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. , 2001, Cytokine.

[87]  M. Tortorella,et al.  The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. , 2001, Osteoarthritis and cartilage.

[88]  Simon A. Jones,et al.  Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage. , 2002, Arthritis and rheumatism.

[89]  E. Lavallie,et al.  ADAMTS4 Cleaves at the Aggrecanase Site (Glu373-Ala374) and Secondarily at the Matrix Metalloproteinase Site (Asn341-Phe342) in the Aggrecan Interglobular Domain* , 2002, Journal of Biological Chemistry.

[90]  S. Santavirta,et al.  Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. , 2002, Arthritis and rheumatism.

[91]  朝倉 正紀 Cardiac Hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF : Metalloproteinase inhibitors as a new therapy , 2002 .

[92]  D. Edwards,et al.  The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. , 2002, Arthritis and rheumatism.

[93]  M. Iruela-Arispe,et al.  ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. , 2002, Biochemical and biophysical research communications.

[94]  R. Maki,et al.  References Subscriptions Permissions Email Alerts Expression and Regulation of Aggrecanase in Arthritis: The Role of TGF- β , 2013 .

[95]  A. Fosang,et al.  The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. , 2002, The Biochemical journal.

[96]  I. Otterness,et al.  Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids. , 2002, Arthritis and rheumatism.

[97]  T. Burn,et al.  Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[98]  M. Covington,et al.  Potent P1' biphenylmethyl substituted aggrecanase inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[99]  J. V. Van Beeumen,et al.  Cloning and Characterization of ADAMTS-14, a Novel ADAMTS Displaying High Homology with ADAMTS-2 and ADAMTS-3* , 2002, The Journal of Biological Chemistry.

[100]  Víctor Quesada,et al.  Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. , 2002, Gene.

[101]  S. Munteanu,et al.  Highly sulfated glycosaminoglycans inhibit aggrecanase degradation of aggrecan by bovine articular cartilage explant cultures. , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[102]  Neil D. Rawlings,et al.  MEROPS: the protease database , 2002, Nucleic Acids Res..

[103]  R. Maki,et al.  Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. , 2002, Journal of immunology.

[104]  P. Roughley,et al.  The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism. , 2002, The Biochemical journal.

[105]  A. Fosang,et al.  Matrix metalloproteinases are active following guanidine hydrochloride extraction of cartilage: generation of DIPEN neoepitope during dialysis. , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[106]  J. Sandy,et al.  Activation of the Proteolytic Activity of ADAMTS4 (Aggrecanase-1) by C-terminal Truncation* , 2002, The Journal of Biological Chemistry.

[107]  E. Arner Aggrecanase-mediated cartilage degradation. , 2002, Current opinion in pharmacology.

[108]  Hiroshi Asanuma,et al.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.

[109]  T. Aigner,et al.  Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. , 2002, Arthritis and rheumatism.

[110]  I. Otterness,et al.  Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. , 2002, Matrix biology : journal of the International Society for Matrix Biology.